1g9m › Citations

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA
Structure 8 1329-39 (2000)
Cited: 287 times
EuropePMC logo PMID: 11188697

Abstract

Background

The gp120 exterior envelope glycoprotein of HIV-1 binds sequentially to CD4 and chemokine receptors on cells to initiate virus entry. During natural infection, gp120 is a primary target of the humoral immune response, and it has evolved to resist antibody-mediated neutralization. We previously reported the structure at 2.5 A of a gp120 core from the HXBc2 laboratory-adapted isolate in complex with a 2 domain fragment of CD4 and the antigen binding fragment of a human antibody. This revealed atomic details of gp120-receptor interactions and suggested multiple mechanisms of immune evasion.

Results

We have now extended the HXBc2 structure in P222, crystals to 2.2 A. The enhanced resolution enabled a more accurate modeling of less-well-ordered regions and provided conclusive identification of the density in the central cavity at the crux of the gp120-CD4 interaction as isopropanol from the crystallization medium. We have also determined the structure of a gp120 core from the primary clinical HIV-1 isolate, YU2, in the same ternary complex but in a C2 crystal lattice. Comparisons of HXBc2 and YU2 showed that while CD4 binding was rigid, portions of the gp120 core were conformationally flexible; overall differences were minor, with sequence changes concentrated on a surface expected to be exposed on the envelope oligomer.

Conclusion

Despite dramatic antigenic differences between primary and laboratory-adapted HIV-1, the gp120 cores from these isolates are remarkably similar. Taken together with chimeric substitution and sequence analysis, this indicates that neutralization resistance is specified by quaternary interactions involving the major variable loops and thus affords a mechanism for viral adaptation. Conservation of the central cavity suggests the possibility of therapeutic inhibitors. The structures reported here extend in detail and generality our understanding of the biology of the gp120 envelope glycoprotein.

Reviews - 1g9m mentioned but not cited (4)

  1. Molecular Mechanism of HIV-1 Entry. Chen B. Trends Microbiol 27 878-891 (2019)
  2. VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. Chen F, Tzarum N, Wilson IA, Law M. Curr Opin Virol 34 149-159 (2019)
  3. Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist. Courter JR, Madani N, Sodroski J, Schön A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, LaLonde JM, Smith AB. Acc Chem Res 47 1228-1237 (2014)
  4. Candidate antibody-based therapeutics against HIV-1. Gong R, Chen W, Dimitrov DS. BioDrugs 26 143-162 (2012)

Articles - 1g9m mentioned but not cited (59)

  1. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC. Cell 153 126-138 (2013)
  2. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Grant OC, Montgomery D, Ito K, Woods RJ. Sci Rep 10 14991 (2020)
  3. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. Gottardo R, Bailer RT, Korber BT, Gnanakaran S, Phillips J, Shen X, Tomaras GD, Turk E, Imholte G, Eckler L, Wenschuh H, Zerweck J, Greene K, Gao H, Berman PW, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robb ML, Michael NL, Kim JH, Zolla-Pazner S, Haynes BF, Mascola JR, Self S, Gilbert P, Montefiori DC. PLoS One 8 e75665 (2013)
  4. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, McKee K, Kong WP, Shi W, Chen X, Todd JP, Letvin NL, Huang J, Nason MC, Hoxie JA, Kwong PD, Connors M, Rao SS, Mascola JR, Nabel GJ. Sci Transl Med 6 243ra88 (2014)
  5. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Dunfee RL, Thomas ER, Gorry PR, Wang J, Taylor J, Kunstman K, Wolinsky SM, Gabuzda D. Proc Natl Acad Sci U S A 103 15160-15165 (2006)
  6. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Madani N, Schön A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower ET, Xiang SH, Kwon YD, Huang CC, Wyatt R, Kwong PD, Freire E, Smith AB, Sodroski J. Structure 16 1689-1701 (2008)
  7. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Sivasubramanian A, Sircar A, Chaudhury S, Gray JJ. Proteins 74 497-514 (2009)
  8. Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Diskin R, Marcovecchio PM, Bjorkman PJ. Nat Struct Mol Biol 17 608-613 (2010)
  9. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, Soeta T, Kobayashi T, Princiotto AM, Wu X, Schön A, Freire E, Kwong PD, Mascola JR, Sodroski J, Madani N, Smith AB. J Med Chem 55 4382-4396 (2012)
  10. Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm. Mayrose I, Shlomi T, Rubinstein ND, Gershoni JM, Ruppin E, Sharan R, Pupko T. Nucleic Acids Res 35 69-78 (2007)
  11. The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. Lynch RM, Rong R, Boliar S, Sethi A, Li B, Mulenga J, Allen S, Robinson JE, Gnanakaran S, Derdeyn CA. J Virol 85 905-915 (2011)
  12. Search for allosteric disulfide bonds in NMR structures. Schmidt B, Hogg PJ. BMC Struct Biol 7 49 (2007)
  13. Prediction of antigenic epitopes on protein surfaces by consensus scoring. Liang S, Zheng D, Zhang C, Zacharias M. BMC Bioinformatics 10 302 (2009)
  14. Human germline antibody gene segments encode polyspecific antibodies. Willis JR, Briney BS, DeLuca SL, Crowe JE, Meiler J. PLoS Comput Biol 9 e1003045 (2013)
  15. Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening. Lalonde JM, Elban MA, Courter JR, Sugawara A, Soeta T, Madani N, Princiotto AM, Kwon YD, Kwong PD, Schön A, Freire E, Sodroski J, Smith AB. Bioorg Med Chem 19 91-101 (2011)
  16. MIMOX: a web tool for phage display based epitope mapping. Huang J, Gutteridge A, Honda W, Kanehisa M. BMC Bioinformatics 7 451 (2006)
  17. Protein dynamics and motions in relation to their functions: several case studies and the underlying mechanisms. Yang LQ, Sang P, Tao Y, Fu YX, Zhang KQ, Xie YH, Liu SQ. J Biomol Struct Dyn 32 372-393 (2014)
  18. Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast. Mata-Fink J, Kriegsman B, Yu HX, Zhu H, Hanson MC, Irvine DJ, Wittrup KD. J Mol Biol 425 444-456 (2013)
  19. Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth. Murphy MK, Yue L, Pan R, Boliar S, Sethi A, Tian J, Pfafferot K, Karita E, Allen SA, Cormier E, Goepfert PA, Borrow P, Robinson JE, Gnanakaran S, Hunter E, Kong XP, Derdeyn CA. PLoS Pathog 9 e1003173 (2013)
  20. Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. Poon AF, Lewis FI, Pond SL, Frost SD. PLoS Comput Biol 3 e11 (2007)
  21. Mining for the antibody-antigen interacting associations that predict the B cell epitopes. Zhao L, Li J. BMC Struct Biol 10 Suppl 1 S6 (2010)
  22. A mechanistic understanding of allosteric immune escape pathways in the HIV-1 envelope glycoprotein. Sethi A, Tian J, Derdeyn CA, Korber B, Gnanakaran S. PLoS Comput Biol 9 e1003046 (2013)
  23. Entropy calculation of HIV-1 Env gp120, its receptor CD4, and their complex: an analysis of configurational entropy changes upon complexation. Hsu ST, Peter C, van Gunsteren WF, Bonvin AM. Biophys J 88 15-24 (2005)
  24. Pep-3D-Search: a method for B-cell epitope prediction based on mimotope analysis. Huang YX, Bao YL, Guo SY, Wang Y, Zhou CG, Li YX. BMC Bioinformatics 9 538 (2008)
  25. The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops. Tsuchiya Y, Mizuguchi K. Protein Sci 25 815-825 (2016)
  26. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Zhou N, Nowicka-Sans B, Zhang S, Fan L, Fang J, Fang H, Gong YF, Eggers B, Langley DR, Wang T, Kadow J, Grasela D, Hanna GJ, Alexander L, Colonno R, Krystal M, Lin PF. Antimicrob Agents Chemother 55 729-737 (2011)
  27. Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies. Bhattacharyya S, Rajan RE, Swarupa Y, Rathore U, Verma A, Udaykumar R, Varadarajan R. J Biol Chem 285 27100-27110 (2010)
  28. Dual-acting stapled peptides target both HIV-1 entry and assembly. Zhang H, Curreli F, Waheed AA, Mercredi PY, Mehta M, Bhargava P, Scacalossi D, Tong X, Lee S, Cooper A, Summers MF, Freed EO, Debnath AK. Retrovirology 10 136 (2013)
  29. Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. Bontjer I, Melchers M, Eggink D, David K, Moore JP, Berkhout B, Sanders RW. J Biol Chem 285 36456-36470 (2010)
  30. MimoPro: a more efficient Web-based tool for epitope prediction using phage display libraries. Chen WH, Sun PP, Lu Y, Guo WW, Huang YX, Ma ZQ. BMC Bioinformatics 12 199 (2011)
  31. Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors. Pacheco B, Basmaciogullari S, Labonte JA, Xiang SH, Sodroski J. J Virol 82 346-357 (2008)
  32. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. Rathore U, Saha P, Kesavardhana S, Kumar AA, Datta R, Devanarayanan S, Das R, Mascola JR, Varadarajan R. J Biol Chem 292 10197-10219 (2017)
  33. Testing the Coulomb/Accessible Surface Area solvent model for protein stability, ligand binding, and protein design. am Busch MS, Lopes A, Amara N, Bathelt C, Simonson T. BMC Bioinformatics 9 148 (2008)
  34. Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange. Cerutti N, Mendelow BV, Napier GB, Papathanasopoulos MA, Killick M, Khati M, Stevens W, Capovilla A. J Biol Chem 285 25743-25752 (2010)
  35. A high-throughput fluorescence polarization assay specific to the CD4 binding site of HIV-1 glycoproteins based on a fluorescein-labelled CD4 mimic. Stricher F, Martin L, Barthe P, Pogenberg V, Mechulam A, Menez A, Roumestand C, Veas F, Royer C, Vita C. Biochem J 390 29-39 (2005)
  36. Structural plasticity and conformational transitions of HIV envelope glycoprotein gp120. Korkut A, Hendrickson WA. PLoS One 7 e52170 (2012)
  37. Epitope prediction based on random peptide library screening: benchmark dataset and prediction tools evaluation. Sun P, Chen W, Huang Y, Wang H, Ma Z, Lv Y. Molecules 16 4971-4993 (2011)
  38. Integrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteins. Zhao Y, Wang Y, Gao Y, Li G, Huang J. PLoS One 10 e0117506 (2015)
  39. Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies. Kaplan G, Roitburd-Berman A, Lewis GK, Gershoni JM. J Virol 90 4481-4493 (2016)
  40. Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. Sanders RW, Hsu ST, van Anken E, Liscaljet IM, Dankers M, Bontjer I, Land A, Braakman I, Bonvin AM, Berkhout B. Mol Biol Cell 19 4707-4716 (2008)
  41. NMR structural analysis of a peptide mimic of the bridging sheet of HIV-1 gp120 in methanol and water. Chakraborty K, Shivakumar P, Raghothama S, Varadarajan R. Biochem J 390 573-581 (2005)
  42. 2-Aminothiazolones as anti-HIV agents that act as gp120-CD4 inhibitors. Tiberi M, Tintori C, Ceresola ER, Fazi R, Zamperini C, Calandro P, Franchi L, Selvaraj M, Botta L, Sampaolo M, Saita D, Ferrarese R, Clementi M, Canducci F, Botta M. Antimicrob Agents Chemother 58 3043-3052 (2014)
  43. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies. Rathore U, Purwar M, Vignesh VS, Das R, Kumar AA, Bhattacharyya S, Arendt H, DeStefano J, Wilson A, Parks C, La Branche CC, Montefiori DC, Varadarajan R. J Biol Chem 293 15002-15020 (2018)
  44. Binding of full-length HIV-1 gp120 to CD4 induces structural reorientation around the gp120 core. Ashish, Garg R, Anguita J, Krueger JK. Biophys J 91 L69-71 (2006)
  45. PepMapper: a collaborative web tool for mapping epitopes from affinity-selected peptides. Chen W, Guo WW, Huang Y, Ma Z. PLoS One 7 e37869 (2012)
  46. Analysis of conformational variation in macromolecular structural models. Srivastava SK, Gayathri S, Manjasetty BA, Gopal B. PLoS One 7 e39993 (2012)
  47. Conformational B-cell epitope prediction method based on antigen preprocessing and mimotopes analysis. Sun P, Ju H, Zhang B, Gu Y, Liu B, Huang Y, Zhang H, Li Y. Biomed Res Int 2015 257030 (2015)
  48. A meta-learning approach for B-cell conformational epitope prediction. Hu YJ, Lin SC, Lin YL, Lin KH, You SN. BMC Bioinformatics 15 378 (2014)
  49. CD4 binding determinant mimicry for HIV vaccine design. Nishiyama Y, Planque S, Hanson CV, Massey RJ, Paul S. Front Immunol 3 383 (2012)
  50. Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. Fellinger CH, Gardner MR, Bailey CC, Farzan M. J Virol 91 e00847-17 (2017)
  51. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. Galkin A, Chen Y, Guenaga J, O'Dell S, Acevedo R, Steinhardt JJ, Wang Y, Wilson R, Chiang CI, Doria-Rose N, Grishaev AV, Mascola JR, Li Y. J Immunol 204 1543-1561 (2020)
  52. Insights into the molecular mechanism underlying CD4-dependency and neutralization sensitivity of HIV-1: a comparative molecular dynamics study on gp120s from isolates with different phenotypes. Li Y, Deng L, Ai SM, Sang P, Yang J, Xia YL, Zhang ZB, Fu YX, Liu SQ. RSC Adv 8 14355-14368 (2018)
  53. Three-Dimensional Visualizations in Teaching Genomics and Bioinformatics: Mutations in HIV Envelope Proteins and Their Consequences for Vaccine Design. Takayama KM. Microbiol Educ 5 3-12 (2004)
  54. Fluctuation dynamics analysis of gp120 envelope protein reveals a topologically based communication network. Shrivastava I, LaLonde JM. Proteins 78 2935-2949 (2010)
  55. Identification of a Human Anti-Alpha-Toxin Monoclonal Antibody Against Staphylococcus aureus Infection. Liu F, Guan Z, Liu Y, Li J, Liu C, Gao Y, Ma Y, Feng J, Shen B, Yang G. Front Microbiol 12 692279 (2021)
  56. Mutational networks of escape from transmitted HIV-1 infection. Akand EH, Maher SJ, Murray JM. PLoS One 15 e0243391 (2020)
  57. research-article Analysis of the SARS-CoV-2 spike protein glycan shield: implications for immune recognition. Grant OC, Montgomery D, Ito K, Woods RJ. bioRxiv 2020.04.07.030445 (2020)
  58. Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope. Ratcliff AN, Venner CM, Olabode AS, Knapp J, Pankrac J, Derecichei I, Gibson RM, Finzi A, Li Y, Mann JFS, Arts EJ. J Virol 96 e0185121 (2022)
  59. Study on molecular mechanisms of CD4 dependency and independency of HIV-1 gp120. Liu MT, Shen JX, Li XW, Yang L, Li Y, Sang P, Yang LQ. RSC Adv 13 6274-6286 (2023)


Reviews citing this publication (32)

  1. GP120: target for neutralizing HIV-1 antibodies. Pantophlet R, Burton DR. Annu Rev Immunol 24 739-769 (2006)
  2. Identifying epitopes of HIV-1 that induce protective antibodies. Zolla-Pazner S. Nat Rev Immunol 4 199-210 (2004)
  3. Antibody vs. HIV in a clash of evolutionary titans. Burton DR, Stanfield RL, Wilson IA. Proc Natl Acad Sci U S A 102 14943-14948 (2005)
  4. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Nature 446 1038-1045 (2007)
  5. Prospects for vaccine protection against HIV-1 infection and AIDS. Letvin NL, Barouch DH, Montefiori DC. Annu Rev Immunol 20 73-99 (2002)
  6. Challenges and opportunities for development of an AIDS vaccine. Nabel GJ. Nature 410 1002-1007 (2001)
  7. HIV entry inhibitors: mechanisms of action and resistance pathways. Briz V, Poveda E, Soriano V. J Antimicrob Chemother 57 619-627 (2006)
  8. A brief history of the global effort to develop a preventive HIV vaccine. Esparza J. Vaccine 31 3502-3518 (2013)
  9. Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Xue B, Mizianty MJ, Kurgan L, Uversky VN. Cell Mol Life Sci 69 1211-1259 (2012)
  10. Proteins that bind high-mannose sugars of the HIV envelope. Botos I, Wlodawer A. Prog Biophys Mol Biol 88 233-282 (2005)
  11. The importance of being flexible: the case of basic region leucine zipper transcriptional regulators. Miller M. Curr Protein Pept Sci 10 244-269 (2009)
  12. Progress in targeting HIV-1 entry. Ryser HJ, Flückiger R. Drug Discov Today 10 1085-1094 (2005)
  13. HIV-1 envelope glycoprotein structure. Merk A, Subramaniam S. Curr Opin Struct Biol 23 268-276 (2013)
  14. Determination of protein-derived epitopes by mass spectrometry. Hager-Braun C, Tomer KB. Expert Rev Proteomics 2 745-756 (2005)
  15. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Korber B, Gnanakaran S. Curr Opin HIV AIDS 4 408-417 (2009)
  16. Reductionism and the search for structure-function relationships in antibody molecules. Van Regenmortel MH. J Mol Recognit 15 240-247 (2002)
  17. Glycosylation of viral surface proteins probed by mass spectrometry. Hargett AA, Renfrow MB. Curr Opin Virol 36 56-66 (2019)
  18. Immunogen design for HIV-1 and influenza. Rathore U, Kesavardhana S, Mallajosyula VV, Varadarajan R. Biochim Biophys Acta 1844 1891-1906 (2014)
  19. HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Acharya P, Lusvarghi S, Bewley CA, Kwong PD. Expert Opin Ther Targets 19 765-783 (2015)
  20. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. Prabakaran P, Dimitrov AS, Fouts TR, Dimitrov DS. Adv Pharmacol 55 33-97 (2007)
  21. Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor. Vermeire K, Schols D. Expert Opin Investig Drugs 14 1199-1212 (2005)
  22. Back to the future: covalent epitope-based HIV vaccine development. Paul S, Planque S, Nishiyama Y, Escobar M, Hanson C. Expert Rev Vaccines 9 1027-1043 (2010)
  23. Physicochemical bases for protein folding, dynamics, and protein-ligand binding. Li H, Xie Y, Liu C, Liu S. Sci China Life Sci 57 287-302 (2014)
  24. Vaccine for AIDS and Ebola virus infection. Nabel GJ. Virus Res 92 213-217 (2003)
  25. Probing Structural Variation and Dynamics in the HIV-1 Env Fusion Glycoprotein. Munro JB, Lee KK. Curr HIV Res 16 5-12 (2018)
  26. Cyclosporin A as a model antigen: immunochemical and structural studies. Altschuh D. J Mol Recognit 15 277-285 (2002)
  27. Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy. Zhou J, Rossi J. J Investig Med 62 914-919 (2014)
  28. Dynamic Viral Glycoprotein Machines: Approaches for Probing Transient States That Drive Membrane Fusion. Garcia NK, Lee KK. Viruses 8 E15 (2016)
  29. Defining and solving the essential protein-protein interactions in HIV infection. Finzi D, Dieffenbach CW, Basavappa R. J Struct Biol 158 148-155 (2007)
  30. Harnessing the protective potential of HIV-1 neutralizing antibodies. Smith SA, Derdeyn CA. F1000Res 5 F1000 Faculty Rev-20 (2016)
  31. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Uversky VN. Arch Virol 166 1283-1296 (2021)
  32. Quaternary Interaction of the HIV-1 Envelope Trimer with CD4 and Neutralizing Antibodies. Liu Q, Zhang P, Lusso P. Viruses 13 1405 (2021)

Articles citing this publication (192)

  1. Antibody neutralization and escape by HIV-1. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Nature 422 307-312 (2003)
  2. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. Nature 420 678-682 (2002)
  3. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Nature 480 336-343 (2011)
  4. Structure of a V3-containing HIV-1 gp120 core. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. Science 310 1025-1028 (2005)
  5. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. J Virol 76 7293-7305 (2002)
  6. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. Nat Med 13 1032-1034 (2007)
  7. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD. Proc Natl Acad Sci U S A 107 1166-1171 (2010)
  8. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. Science 326 1123-1127 (2009)
  9. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, Leseka N, Treurnicht F, Mlisana K, Shaw GM, Karim SS, Williamson C, Morris L, CAPRISA 002 Study Team, CAPRISA 002 Study Team. J Virol 81 6187-6196 (2007)
  10. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Huang CC, Venturi M, Majeed S, Moore MJ, Phogat S, Zhang MY, Dimitrov DS, Hendrickson WA, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, Kwong PD. Proc Natl Acad Sci U S A 101 2706-2711 (2004)
  11. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S, Macleod K, O'Shea A, Patel N, Van Ryk D, Wei D, Pascuccio M, Yi L, McKinnon L, Izulla P, Kimani J, Kaul R, Fauci AS, Arthos J. Proc Natl Acad Sci U S A 106 20877-20882 (2009)
  12. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Mol Ther 16 1481-1489 (2008)
  13. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. Proc Natl Acad Sci U S A 109 5663-5668 (2012)
  14. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. Tran EE, Borgnia MJ, Kuybeda O, Schauder DM, Bartesaghi A, Frank GA, Sapiro G, Milne JL, Subramaniam S. PLoS Pathog 8 e1002797 (2012)
  15. Few and far between: how HIV may be evading antibody avidity. Klein JS, Bjorkman PJ. PLoS Pathog 6 e1000908 (2010)
  16. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E, Robinson JE, Gnanakaran S, Derdeyn CA. PLoS Pathog 5 e1000594 (2009)
  17. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK. Virology 339 213-225 (2005)
  18. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA. Structure 12 193-204 (2004)
  19. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Koch M, Pancera M, Kwong PD, Kolchinsky P, Grundner C, Wang L, Hendrickson WA, Sodroski J, Wyatt R. Virology 313 387-400 (2003)
  20. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, Zolla-Pazner S. AIDS Res Hum Retroviruses 23 415-426 (2007)
  21. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. AIDS Res Hum Retroviruses 18 1207-1217 (2002)
  22. Mechanism of membrane fusion by viral envelope proteins. Harrison SC. Adv Virus Res 64 231-261 (2005)
  23. Alternative conformations of HIV-1 V3 loops mimic beta hairpins in chemokines, suggesting a mechanism for coreceptor selectivity. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Görlach M, Anglister J. Structure 11 225-236 (2003)
  24. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. Guo Q, Ho HT, Dicker I, Fan L, Zhou N, Friborg J, Wang T, McAuliffe BV, Wang HG, Rose RE, Fang H, Scarnati HT, Langley DR, Meanwell NA, Abraham R, Colonno RJ, Lin PF. J Virol 77 10528-10536 (2003)
  25. The development of CD4 binding site antibodies during HIV-1 infection. Lynch RM, Tran L, Louder MK, Schmidt SD, Cohen M, CHAVI 001 Clinical Team Members, Dersimonian R, Euler Z, Gray ES, Abdool Karim S, Kirchherr J, Montefiori DC, Sibeko S, Soderberg K, Tomaras G, Yang ZY, Nabel GJ, Schuitemaker H, Morris L, Haynes BF, Mascola JR. J Virol 86 7588-7595 (2012)
  26. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T, Gaschen B, Krishnamoorthy M, Li H, Decker JM, Salazar-Gonzalez JF, Wang S, Jiang C, Gao F, Swanstrom R, Anderson JA, Ping LH, Cohen MS, Markowitz M, Goepfert PA, Saag MS, Eron JJ, Hicks CB, Blattner WA, Tomaras GD, Asmal M, Letvin NL, Gilbert PB, Decamp AC, Magaret CA, Schief WR, Ban YE, Zhang M, Soderberg KA, Sodroski JG, Haynes BF, Shaw GM, Hahn BH, Korber B. PLoS Pathog 7 e1002209 (2011)
  27. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. Pantophlet R, Wilson IA, Burton DR. J Virol 77 5889-5901 (2003)
  28. Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. Guttman M, Cupo A, Julien JP, Sanders RW, Wilson IA, Moore JP, Lee KK. Nat Commun 6 6144 (2015)
  29. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Ramessar K, Rademacher T, Sack M, Stadlmann J, Platis D, Stiegler G, Labrou N, Altmann F, Ma J, Stöger E, Capell T, Christou P. Proc Natl Acad Sci U S A 105 3727-3732 (2008)
  30. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. Reeves JD, Miamidian JL, Biscone MJ, Lee FH, Ahmad N, Pierson TC, Doms RW. J Virol 78 5476-5485 (2004)
  31. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Huang CC, Stricher F, Martin L, Decker JM, Majeed S, Barthe P, Hendrickson WA, Robinson J, Roumestand C, Sodroski J, Wyatt R, Shaw GM, Vita C, Kwong PD. Structure 13 755-768 (2005)
  32. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. Rong R, Gnanakaran S, Decker JM, Bibollet-Ruche F, Taylor J, Sfakianos JN, Mokili JL, Muldoon M, Mulenga J, Allen S, Hahn BH, Shaw GM, Blackwell JL, Korber BT, Hunter E, Derdeyn CA. J Virol 81 5658-5668 (2007)
  33. Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. Kulkarni SS, Lapedes A, Tang H, Gnanakaran S, Daniels MG, Zhang M, Bhattacharya T, Li M, Polonis VR, McCutchan FE, Morris L, Ellenberger D, Butera ST, Bollinger RC, Korber BT, Paranjape RS, Montefiori DC. Virology 385 505-520 (2009)
  34. Congress Antibody-based HIV-1 vaccines: recent developments and future directions. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J, Working Group convened by the Global HIV Vaccine Enterprise. PLoS Med 4 e348 (2007)
  35. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes BF, Cohen MS, Shaw GM, Seaman MS, Kumar A, Gao F, Montefiori DC, Korber B. PLoS Comput Biol 6 e1000955 (2010)
  36. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Liu Q, Acharya P, Dolan MA, Zhang P, Guzzo C, Lu J, Kwon A, Gururani D, Miao H, Bylund T, Chuang GY, Druz A, Zhou T, Rice WJ, Wigge C, Carragher B, Potter CS, Kwong PD, Lusso P. Nat Struct Mol Biol 24 370-378 (2017)
  37. The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP. Virology 321 8-22 (2004)
  38. The mapping and reconstitution of a conformational discontinuous B-cell epitope of HIV-1. Enshell-Seijffers D, Denisov D, Groisman B, Smelyanski L, Meyuhas R, Gross G, Denisova G, Gershoni JM. J Mol Biol 334 87-101 (2003)
  39. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, Wilson IA. J Mol Biol 375 969-978 (2008)
  40. Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity. Liu L, Patel B, Ghanem MH, Bundoc V, Zheng Z, Morgan RA, Rosenberg SA, Dey B, Berger EA. J Virol 89 6685-6694 (2015)
  41. 3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins. Schreiber A, Humbert M, Benz A, Dietrich U. J Comput Chem 26 879-887 (2005)
  42. Appreciating HIV type 1 diversity: subtype differences in Env. Lynch RM, Shen T, Gnanakaran S, Derdeyn CA. AIDS Res Hum Retroviruses 25 237-248 (2009)
  43. Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. Gnanakaran S, Lang D, Daniels M, Bhattacharya T, Derdeyn CA, Korber B. J Virol 81 4886-4891 (2007)
  44. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. Si Z, Cayabyab M, Sodroski J. J Virol 75 4208-4218 (2001)
  45. Mapping mutational effects along the evolutionary landscape of HIV envelope. Haddox HK, Dingens AS, Hilton SK, Overbaugh J, Bloom JD. Elife 7 e34420 (2018)
  46. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, Mishra R, Pease B, Hansen E, Singh J, Zembower D, Kim H, Kiselyov AS, Burgin AB, Gurney ME, Stewart LJ. J Med Chem 52 4694-4715 (2009)
  47. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Williams WB, Zhang J, Jiang C, Nicely NI, Fera D, Luo K, Moody MA, Liao HX, Alam SM, Kepler TB, Ramesh A, Wiehe K, Holland JA, Bradley T, Vandergrift N, Saunders KO, Parks R, Foulger A, Xia SM, Bonsignori M, Montefiori DC, Louder M, Eaton A, Santra S, Scearce R, Sutherland L, Newman A, Bouton-Verville H, Bowman C, Bomze H, Gao F, Marshall DJ, Whitesides JF, Nie X, Kelsoe G, Reed SG, Fox CB, Clary K, Koutsoukos M, Franco D, Mascola JR, Harrison SC, Haynes BF, Verkoczy L. Nat Commun 8 1732 (2017)
  48. Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Yang X, Mahony E, Holm GH, Kassa A, Sodroski J. Virology 313 117-125 (2003)
  49. An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Sterjovski J, Roche M, Churchill MJ, Ellett A, Farrugia W, Gray LR, Cowley D, Poumbourios P, Lee B, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR. Virology 404 269-278 (2010)
  50. Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. Dacheux L, Moreau A, Ataman-Onal Y, Biron F, Verrier B, Barin F. J Virol 78 12625-12637 (2004)
  51. Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure 13 197-211 (2005)
  52. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, Kramer VG, Lakhashe S, Santosuosso M, Poznansky MC, Novembre FJ, Villinger F, Else JG, Montefiori DC, Rasmussen RA, Ruprecht RM. PLoS One 5 e11689 (2010)
  53. Automated detection of conformational epitopes using phage display Peptide sequences. Negi SS, Braun W. Bioinform Biol Insights 3 71-81 (2009)
  54. Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein. Stricher F, Huang CC, Descours A, Duquesnoy S, Combes O, Decker JM, Kwon YD, Lusso P, Shaw GM, Vita C, Kwong PD, Martin L. J Mol Biol 382 510-524 (2008)
  55. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Kang SM, Quan FS, Huang C, Guo L, Ye L, Yang C, Compans RW. Virology 331 20-32 (2005)
  56. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. Désormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, Gu C, Xiang SH, Mao Y, Sodroski J, Finzi A. J Virol 87 2549-2562 (2013)
  57. An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins. Ren X, Sodroski J, Yang X. J Virol 79 5616-5624 (2005)
  58. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design. Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, Sinha P, Yadav R, Rashid U, Kennedy S, Eckert D, Geleziunas R, Bramhill D, Schleif W, Liang X, Shiver J. J Virol 79 1713-1723 (2005)
  59. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB. J Virol 84 1683-1695 (2010)
  60. Molecular recognition of CCR5 by an HIV-1 gp120 V3 loop. Tamamis P, Floudas CA. PLoS One 9 e95767 (2014)
  61. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW. J Virol 83 368-383 (2009)
  62. Crystal structure of a fully glycosylated HIV-1 gp120 core reveals a stabilizing role for the glycan at Asn262. Kong L, Wilson IA, Kwong PD. Proteins 83 590-596 (2015)
  63. Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36. Sun M, Pace CS, Yao X, Yu F, Padte NN, Huang Y, Seaman MS, Li Q, Ho DD. J Acquir Immune Defic Syndr 66 473-483 (2014)
  64. Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold. Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S. Virology 405 513-523 (2010)
  65. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, Sodroski J. J Virol Methods 168 155-161 (2010)
  66. Interdomain Stabilization Impairs CD4 Binding and Improves Immunogenicity of the HIV-1 Envelope Trimer. Zhang P, Gorman J, Geng H, Liu Q, Lin Y, Tsybovsky Y, Go EP, Dey B, Andine T, Kwon A, Patel M, Gururani D, Uddin F, Guzzo C, Cimbro R, Miao H, McKee K, Chuang GY, Martin L, Sironi F, Malnati MS, Desaire H, Berger EA, Mascola JR, Dolan MA, Kwong PD, Lusso P. Cell Host Microbe 23 832-844.e6 (2018)
  67. Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop. Stanfield RL, Ghiara JB, Ollmann Saphire E, Profy AT, Wilson IA. Virology 315 159-173 (2003)
  68. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N, Princiotto AM, Zhao C, Jahanbakhshsefidi F, Mertens M, Herschhorn A, Melillo B, Smith AB, Sodroski J. J Virol 91 e01880-16 (2017)
  69. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4. Yang QE, Stephen AG, Adelsberger JW, Roberts PE, Zhu W, Currens MJ, Feng Y, Crise BJ, Gorelick RJ, Rein AR, Fisher RJ, Shoemaker RH, Sei S. J Virol 79 6122-6133 (2005)
  70. Enhancing protein crystallization through precipitant synergy. Majeed S, Ofek G, Belachew A, Huang CC, Zhou T, Kwong PD. Structure 11 1061-1070 (2003)
  71. Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies. Pantophlet R, Burton DR. Trends Mol Med 9 468-473 (2003)
  72. Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. Xiang SH, Farzan M, Si Z, Madani N, Wang L, Rosenberg E, Robinson J, Sodroski J. J Virol 79 6068-6077 (2005)
  73. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ. J Mol Biol 350 699-712 (2005)
  74. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/deuterium exchange. Kong L, Huang CC, Coales SJ, Molnar KS, Skinner J, Hamuro Y, Kwong PD. J Virol 84 10311-10321 (2010)
  75. Molecular recognition of CXCR4 by a dual tropic HIV-1 gp120 V3 loop. Tamamis P, Floudas CA. Biophys J 105 1502-1514 (2013)
  76. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D. Virology 360 294-304 (2007)
  77. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. Gopi H, Umashankara M, Pirrone V, LaLonde J, Madani N, Tuzer F, Baxter S, Zentner I, Cocklin S, Jawanda N, Miller SR, Schön A, Klein JC, Freire E, Krebs FC, Smith AB, Sodroski J, Chaiken I. J Med Chem 51 2638-2647 (2008)
  78. Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus. Xie H, Ng D, Savinov SN, Dey B, Kwong PD, Wyatt R, Smith AB, Hendrickson WA. J Med Chem 50 4898-4908 (2007)
  79. Atomic insight into the CD4 binding-induced conformational changes in HIV-1 gp120. Hsu ST, Bonvin AM. Proteins 55 582-593 (2004)
  80. Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. Cocklin S, Gopi H, Querido B, Nimmagadda M, Kuriakose S, Cicala C, Ajith S, Baxter S, Arthos J, Martín-García J, Chaiken IM. J Virol 81 3645-3648 (2007)
  81. CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120-CD4 interactions and fusogenicity. Sterjovski J, Churchill MJ, Roche M, Ellett A, Farrugia W, Wesselingh SL, Cunningham AL, Ramsland PA, Gorry PR. Virology 410 418-428 (2011)
  82. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Nandi A, Lavine CL, Wang P, Lipchina I, Goepfert PA, Shaw GM, Tomaras GD, Montefiori DC, Haynes BF, Easterbrook P, Robinson JE, Sodroski JG, Yang X, NIAID Center for HIV/AIDS Vaccine Immunology. Virology 396 339-348 (2010)
  83. Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4. Ryzhova E, Whitbeck JC, Canziani G, Westmoreland SV, Cohen GH, Eisenberg RJ, Lackner A, González-Scarano F. J Virol 76 7903-7909 (2002)
  84. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates. Lagenaur LA, Villarroel VA, Bundoc V, Dey B, Berger EA. Retrovirology 7 11 (2010)
  85. CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Narumi T, Arai H, Yoshimura K, Harada S, Hirota Y, Ohashi N, Hashimoto C, Nomura W, Matsushita S, Tamamura H. Bioorg Med Chem 21 2518-2526 (2013)
  86. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope. Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA. J Virol 89 8130-8151 (2015)
  87. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. Humbert M, Rasmussen RA, Ong H, Kaiser FM, Hu SL, Ruprecht RM. PLoS One 3 e3937 (2008)
  88. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120. Davenport TM, Guttman M, Guo W, Cleveland B, Kahn M, Hu SL, Lee KK. J Virol 87 10855-10873 (2013)
  89. Longitudinal Analysis of CCR5 and CXCR4 Usage in a Cohort of Antiretroviral Therapy-Naïve Subjects with Progressive HIV-1 Subtype C Infection. Jakobsen MR, Cashin K, Roche M, Sterjovski J, Ellett A, Borm K, Flynn J, Erikstrup C, Gouillou M, Gray LR, Saksena NK, Wang B, Purcell DF, Kallestrup P, Zinyama-Gutsire R, Gomo E, Ullum H, Ostergaard L, Lee B, Ramsland PA, Churchill MJ, Gorry PR. PLoS One 8 e65950 (2013)
  90. The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012. Zhu CB, Zhu L, Holz-Smith S, Matthews TJ, Chen CH. Proc Natl Acad Sci U S A 98 15227-15232 (2001)
  91. Disulfide bond that constrains the HIV-1 gp120 V3 domain is cleaved by thioredoxin. Azimi I, Matthias LJ, Center RJ, Wong JW, Hogg PJ. J Biol Chem 285 40072-40080 (2010)
  92. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Humbert M, Antoni S, Brill B, Landersz M, Rodes B, Soriano V, Wintergerst U, Knechten H, Staszewski S, von Laer D, Dittmar MT, Dietrich U. Eur J Immunol 37 501-515 (2007)
  93. Letter Structure of trimeric HIV-1 envelope glycoproteins. Subramaniam S. Proc Natl Acad Sci U S A 110 E4172-4 (2013)
  94. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. Platt EJ, Shea DM, Rose PP, Kabat D. J Virol 79 4357-4368 (2005)
  95. Small molecular CD4 mimics as HIV entry inhibitors. Narumi T, Arai H, Yoshimura K, Harada S, Nomura W, Matsushita S, Tamamura H. Bioorg Med Chem 19 6735-6742 (2011)
  96. Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Ding J, Smith AD, Geisler SC, Ma X, Arnold GF, Arnold E. Structure 10 999-1011 (2002)
  97. The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions. Pantophlet R, Wang M, Aguilar-Sino RO, Burton DR. J Virol 83 1649-1659 (2009)
  98. Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity. Cimbro R, Gallant TR, Dolan MA, Guzzo C, Zhang P, Lin Y, Miao H, Van Ryk D, Arthos J, Gorshkova I, Brown PH, Hurt DE, Lusso P. Proc Natl Acad Sci U S A 111 3152-3157 (2014)
  99. Binding thermodynamics of the N-terminal peptide of the CCR5 coreceptor to HIV-1 envelope glycoprotein gp120. Brower ET, Schön A, Klein JC, Freire E. Biochemistry 48 779-785 (2009)
  100. Derivation and characterization of a simian immunodeficiency virus SIVmac239 variant with tropism for CXCR4. Del Prete GQ, Haggarty B, Leslie GJ, Jordan AP, Romano J, Wang N, Wang J, Holmes MC, Montefiori DC, Hoxie JA. J Virol 83 9911-9922 (2009)
  101. Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. Mancia F, Brenner-Morton S, Siegel R, Assur Z, Sun Y, Schieren I, Mendelsohn M, Axel R, Hendrickson WA. Proc Natl Acad Sci U S A 104 4303-4308 (2007)
  102. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Teixeira C, Serradji N, Maurel F, Barbault F. Eur J Med Chem 44 3524-3532 (2009)
  103. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, Corti D, Wallace A, Wang S, Kong XP, Lu S, Clapham PR. J Virol 87 187-198 (2013)
  104. Heavy chain-only IgG2b llama antibody effects near-pan HIV-1 neutralization by recognizing a CD4-induced epitope that includes elements of coreceptor- and CD4-binding sites. Acharya P, Luongo TS, Georgiev IS, Matz J, Schmidt SD, Louder MK, Kessler P, Yang Y, McKee K, O'Dell S, Chen L, Baty D, Chames P, Martin L, Mascola JR, Kwong PD. J Virol 87 10173-10181 (2013)
  105. Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet. Schiavone M, Fiume G, Caivano A, De Laurentiis A, Falcone C, Masci FF, Iaccino E, Mimmi S, Palmieri C, Pisano A, Pontoriero M, Rossi A, Scialdone A, Vecchio E, Andreozzi C, Trovato M, Rafay J, Ferko B, Montefiori D, Lombardi A, Morsica G, Poli G, Quinto I, Pavone V, De Berardinis P, Scala G. Int J Mol Sci 13 5674-5699 (2012)
  106. Structural analysis of a highly glycosylated and unliganded gp120-based antigen using mass spectrometry. Wang L, Qin Y, Ilchenko S, Bohon J, Shi W, Cho MW, Takamoto K, Chance MR. Biochemistry 49 9032-9045 (2010)
  107. Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection. Lynch RM, Rong R, Li B, Shen T, Honnen W, Mulenga J, Allen S, Pinter A, Gnanakaran S, Derdeyn CA. Virology 404 59-70 (2010)
  108. The SIV surface spike imaged by electron tomography: one leg or three? Subramaniam S. PLoS Pathog 2 e91 (2006)
  109. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction. Wendt MD. Expert Opin Drug Discov 3 1123-1143 (2008)
  110. Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120. Mirano-Bascos D, Steede NK, Robinson JE, Landry SJ. J Virol 84 3303-3311 (2010)
  111. Neutralization of HIV-1 by redirection of natural antibodies. Perdomo MF, Levi M, Sällberg M, Vahlne A. Proc Natl Acad Sci U S A 105 12515-12520 (2008)
  112. Computational Refinement and Validation Protocol for Proteins with Large Variable Regions Applied to Model HIV Env Spike in CD4 and 17b Bound State. Rasheed M, Bettadapura R, Bajaj C. Structure 23 1138-1149 (2015)
  113. Importance of V3 loop flexibility and net charge in the context of co-receptor recognition. A molecular dynamics study on HIV gp120. Chandramouli B, Chillemi G, Abbate I, Capobianchi MR, Rozera G, Desideri A. J Biomol Struct Dyn 29 879-891 (2012)
  114. Insights into the structure, correlated motions, and electrostatic properties of two HIV-1 gp120 V3 loops. López de Victoria A, Tamamis P, Kieslich CA, Morikis D. PLoS One 7 e49925 (2012)
  115. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW. PLoS One 8 e76139 (2013)
  116. A twin-cysteine motif in the V2 region of gp120 is associated with SIV envelope trimer stabilization. Bohl C, Bowder D, Thompson J, Abrahamyan L, Gonzalez-Ramirez S, Mao Y, Sodroski J, Wood C, Xiang SH. PLoS One 8 e69406 (2013)
  117. Neutralization efficiency is greatly enhanced by bivalent binding of an antibody to epitopes in the V4 region and the membrane-proximal external region within one trimer of human immunodeficiency virus type 1 glycoproteins. Wang P, Yang X. J Virol 84 7114-7123 (2010)
  118. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions. McFadden K, Cocklin S, Gopi H, Baxter S, Ajith S, Mahmood N, Shattock R, Chaiken I. Proteins 67 617-629 (2007)
  119. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Caporuscio F, Tafi A, González E, Manetti F, Esté JA, Botta M. Bioorg Med Chem Lett 19 6087-6091 (2009)
  120. Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins. Lewis GK, Fouts TR, Ibrahim S, Taylor BM, Salkar R, Guan Y, Kamin-Lewis R, Robinson JE, Devico AL. J Virol 85 13097-13104 (2011)
  121. Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. Morellato-Castillo L, Acharya P, Combes O, Michiels J, Descours A, Ramos OH, Yang Y, Vanham G, Ariën KK, Kwong PD, Martin L, Kessler P. J Med Chem 56 5033-5047 (2013)
  122. Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors. Brower ET, Schön A, Freire E. Biochemistry 49 2359-2367 (2010)
  123. Stability and Water Accessibility of the Trimeric Membrane Anchors of the HIV-1 Envelope Spikes. Piai A, Dev J, Fu Q, Chou JJ. J Am Chem Soc 139 18432-18435 (2017)
  124. AutoMatch: target-binding protein design and enzyme design by automatic pinpointing potential active sites in available protein scaffolds. Zhang C, Lai L. Proteins 80 1078-1094 (2012)
  125. Bioinformatic analysis of neurotropic HIV envelope sequences identifies polymorphisms in the gp120 bridging sheet that increase macrophage-tropism through enhanced interactions with CCR5. Mefford ME, Kunstman K, Wolinsky SM, Gabuzda D. Virology 481 210-222 (2015)
  126. CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo. Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG. J Virol 87 9719-9732 (2013)
  127. Direct impact of inactivated HIV-1 virions on B lymphocyte subsets. Viau M, Veas F, Zouali M. Mol Immunol 44 2124-2134 (2007)
  128. Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120. Shrivastava IH, Wendel K, LaLonde JM. Biochemistry 51 7783-7793 (2012)
  129. Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues. Gray L, Sterjovski J, Ramsland PA, Churchill MJ, Gorry PR. Retrovirology 8 42 (2011)
  130. Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain. Newman JT, Sturgeon TJ, Gupta P, Montelaro RC. Virology 367 102-116 (2007)
  131. Enhanced dynamics of HIV gp120 glycoprotein by small molecule binding. Shrivastava I, LaLonde JM. Biochemistry 50 4173-4183 (2011)
  132. Molecular docking guided structure based design of symmetrical N,N'-disubstituted urea/thiourea as HIV-1 gp120-CD4 binding inhibitors. Sivan SK, Vangala R, Manga V. Bioorg Med Chem 21 4591-4599 (2013)
  133. Putative rhesus macaque germline predecessors of human broadly HIV-neutralizing antibodies: differences from the human counterparts and implications for HIV-1 vaccine development. Yuan T, Li J, Zhang Y, Wang Y, Streaker E, Dimitrov DS, Zhang MY. Vaccine 29 6903-6910 (2011)
  134. Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. Cimbro R, Peterson FC, Liu Q, Guzzo C, Zhang P, Miao H, Van Ryk D, Ambroggio X, Hurt DE, De Gioia L, Volkman BF, Dolan MA, Lusso P. EBioMedicine 10 45-54 (2016)
  135. A rationally designed synthetic mimic of the discontinuous CD4-binding site of HIV-1 gp120. Franke R, Hirsch T, Eichler J. J Recept Signal Transduct Res 26 453-460 (2006)
  136. Scaffold optimization in discontinuous epitope containing protein mimics of gp120 using smart libraries. Mulder GE, Quarles van Ufford HL, van Ameijde J, Brouwer AJ, Kruijtzer JA, Liskamp RM. Org Biomol Chem 11 2676-2684 (2013)
  137. Stability of a receptor-binding active human immunodeficiency virus type 1 recombinant gp140 trimer conferred by intermonomer disulfide bonding of the V3 loop: differential effects of protein disulfide isomerase on CD4 and coreceptor binding. Billington J, Hickling TP, Munro GH, Halai C, Chung R, Dodson GG, Daniels RS. J Virol 81 4604-4614 (2007)
  138. Tetrahydrocurcumin-loaded vaginal nanomicrobicide for prophylaxis of HIV/AIDS: in silico study, formulation development, and in vitro evaluation. Mirani A, Kundaikar H, Velhal S, Patel V, Bandivdekar A, Degani M, Patravale V. Drug Deliv Transl Res 9 828-847 (2019)
  139. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Da LT, Quan JM, Wu YD. Proteins 79 1810-1819 (2011)
  140. A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. Zhao Q, He Y, Alespeiti G, Debnath AK. Virology 326 299-309 (2004)
  141. Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. Rawi R, Kunji K, Haoudi A, Bensmail H. PLoS One 10 e0143245 (2015)
  142. Fold recognition of the human immunodeficiency virus type 1 V3 loop and flexibility of its crown structure during the course of adaptation to a host. Watabe T, Kishino H, Okuhara Y, Kitazoe Y. Genetics 172 1385-1396 (2006)
  143. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters. Azizi A, Anderson DE, Ghorbani M, Gee K, Diaz-Mitoma F. BMC Immunol 7 25 (2006)
  144. Insight derived from molecular dynamics simulations into molecular motions, thermodynamics and kinetics of HIV-1 gp120. Sang P, Yang LQ, Ji XL, Fu YX, Liu SQ. PLoS One 9 e104714 (2014)
  145. Low complexity regions (LCRs) contribute to the hypervariability of the HIV-1 gp120 protein. María Velasco A, Becerra A, Hernández-Morales R, Delaye L, Jiménez-Corona ME, Ponce-de-Leon S, Lazcano A. J Theor Biol 338 80-86 (2013)
  146. Molecular construction of HIV-gp120 discontinuous epitope mimics by assembly of cyclic peptides on an orthogonal alkyne functionalized TAC-scaffold. Werkhoven PR, Elwakiel M, Meuleman TJ, Quarles van Ufford HC, Kruijtzer JAW, Liskamp RMJ. Org Biomol Chem 14 701-710 (2016)
  147. Molecular motions in HIV-1 gp120 mutants reveal their preferences for different conformations. Liu SQ, Liu CQ, Fu YX. J Mol Graph Model 26 306-318 (2007)
  148. Structural dynamics of V3 loop with different electrostatics: implications on co-receptor recognition: a molecular dynamics study of HIV gp120. Chandramouli B, Chillemi G, Giombini E, Capobianchi MR, Rozera G, Desideri A. J Biomol Struct Dyn 31 403-413 (2013)
  149. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Tanaka K, Kuwata T, Alam M, Kaplan G, Takahama S, Valdez KPR, Roitburd-Berman A, Gershoni JM, Matsushita S. Retrovirology 14 44 (2017)
  150. Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120. Lee HS, Contarino M, Umashankara M, Schön A, Freire E, Smith AB, Chaiken IM, Penn LS. Anal Bioanal Chem 396 1143-1152 (2010)
  151. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection. Fontenot D, Jones JK, Hossain MM, Nehete PN, Vela EM, Dwyer VA, Jagannadha Sastry K. Virology 363 69-78 (2007)
  152. Evidence for Selection of more Adapted Human Immunodeficiency Virus Type 1 Recombinant Strains in a Dually Infected Transfusion Recipient. Costa LJ, Mayer AJ, Busch MP, Diaz RS. Virus Genes 28 259-272 (2004)
  153. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. Qualls ZM, Choudhary A, Honnen W, Prattipati R, Robinson JE, Pinter A. J Virol 92 e01779-17 (2018)
  154. Peptides selected from a phage display library with an HIV-neutralizing antibody elicit antibodies to HIV gp120 in rabbits, but not to the same epitope. Wilkinson RA, Evans JR, Jacobs JM, Slunaker D, Pincus SH, Pinter A, Parkos CA, Burritt JB, Teintze M. AIDS Res Hum Retroviruses 23 1416-1427 (2007)
  155. Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1. Babaahmady K, Bergmeier LA, Lehner T. AIDS 22 1267-1276 (2008)
  156. Computational studies identifying entry inhibitor scaffolds targeting the Phe43 cavity of HIV-1 gp120. Tintori C, Selvaraj M, Badia R, Clotet B, Esté JA, Botta M. ChemMedChem 8 475-483 (2013)
  157. Conservation of inner domain modules in the surface envelope glycoproteins of an ancient rabbit lentivirus and extant lentiviruses and betaretroviruses. Hötzel I. Virology 372 201-207 (2008)
  158. Dynamic domains and geometrical properties of HIV-1 gp120 during conformational changes induced by CD4 binding. Liu SQ, Liu SX, Fu YX. J Mol Model 13 411-424 (2007)
  159. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys. Yeh WW, Brassard LM, Miller CA, Basavapathruni A, Zhang J, Rao SS, Nabel GJ, Mascola JR, Letvin NL, Seaman MS. J Virol 86 7052-7059 (2012)
  160. Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120. Meier J, Kassler K, Sticht H, Eichler J. Beilstein J Org Chem 8 1858-1866 (2012)
  161. The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations. Li L, Chen H, Zhao RN, Han JG. J Mol Model 19 905-917 (2013)
  162. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18. Gift SK, Zentner IJ, Schön A, McFadden K, Umashankara M, Rajagopal S, Contarino M, Duffy C, Courter JR, Zhang MY, Gershoni JM, Cocklin S, Dimitrov DS, Smith AB, Freire E, Chaiken IM. Biochemistry 50 2756-2768 (2011)
  163. Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigm. Hurevich M, Swed A, Joubran S, Cohen S, Freeman NS, Britan-Rosich E, Briant-Longuet L, Bardy M, Devaux C, Kotler M, Hoffman A, Gilon C. Bioorg Med Chem 18 5754-5761 (2010)
  164. Role of CD4 hinge region in GP120 utilization by immunoglobulin domain 1. Murray JL, Hu QX, Navenot JM, Peiper SC. Biochem Biophys Res Commun 292 449-455 (2002)
  165. A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain α1 helix in an engineered HIV-1 gp120. Emileh A, Abrams CF. Proteins 79 537-546 (2011)
  166. A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4. Duan LW, Zhang H, Zhao MT, Sun JX, Chen WL, Lin JP, Liu XQ. Sci Rep 7 46733 (2017)
  167. Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis. Hager-Braun C, Hochleitner EO, Gorny MK, Zolla-Pazner S, Bienstock RJ, Tomer KB. J Am Soc Mass Spectrom 21 1687-1698 (2010)
  168. Conservancy of the α4β7 integrin mimotope in the V2 domain of HIV type 1 CRF07_BC compared to subtype B' strains in China. He X, Mokili JL, Hong K, Chen J, Wei J, Xin R, Song YH, Feng Y, Jia M, Xing H, Shao Y. AIDS Res Hum Retroviruses 27 1127-1133 (2011)
  169. Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving. Andrianov AM. Expert Opin Drug Discov 6 419-435 (2011)
  170. Comment Picking the lock with a hairpin. Did HIV-1 learn the art from chemokines? Lusso P. Structure 11 129-130 (2003)
  171. Roles of conserved tryptophans in trimerization of HIV-1 membrane-proximal external regions: Implications for virucidal design via alchemical free-energy molecular simulations. Gossert ST, Parajuli B, Chaiken I, Abrams CF. Proteins 86 707-711 (2018)
  172. Structural Basis for Species Selectivity in the HIV-1 gp120-CD4 Interaction: Restoring Affinity to gp120 in Murine CD4 Mimetic Peptides. Kassler K, Meier J, Eichler J, Sticht H. Adv Bioinformatics 2011 736593 (2011)
  173. Structural dynamics of V3 loop in a trimeric ambiance, a molecular dynamics study on gp120-CD4 trimeric mimic. Chandramouli B, Chillemi G, Desideri A. J Struct Biol 186 132-140 (2014)
  174. Systematic protein-protein docking and molecular dynamics studies of HIV-1 gp120 and CD4: insights for new drug development. Chong Teoh T, Heidelberg T, Rizman-Idid M. Daru 19 469-475 (2011)
  175. Blocking HIV-1 gp120 at the Phe43 cavity: if the extension fits…. Dey B, Berger EA. Structure 21 871-872 (2013)
  176. Creating a community resource for protein science. Berman HM. Protein Sci 21 1587-1596 (2012)
  177. Fusion/entry inhibitors as therapies for HIV. Redshaw S, Westby M. Expert Opin Emerg Drugs 6 209-224 (2001)
  178. HIV-2 neutralization by intact V3-specific Fab fragments. Sourial S, Nilsson C. Virol J 5 96 (2008)
  179. Is the conformational flexibility of piperazine derivatives important to inhibit HIV-1 replication? Teixeira C, Serradji N, Amroune S, Storck K, Rogez-Kreuz C, Clayette P, Barbault F, Maurel F. J Mol Graph Model 44 91-103 (2013)
  180. Roles of variable linker length in dual acting virucidal entry inhibitors on HIV-1 potency via on-the-fly free energy molecular simulations. Gossert ST, Parajuli B, Chaiken I, Abrams CF. Protein Sci 29 2304-2310 (2020)
  181. Structure and design of broadly-neutralizing antibodies against HIV. Ryu SE, Hendrickson WA. Mol Cells 34 231-237 (2012)
  182. The evolutionary significance of certain amino acid substitutions and their consequences for HIV-1 immunogenicity toward HLA's A*0201 and B*27. Hecht L, Dormer A. Bioinformation 9 315-320 (2013)
  183. Functional chimeras of human immunodeficiency virus type 1 Gp120 and influenza A virus (H3) hemagglutinin. Copeland KM, Elliot AJ, Daniels RS. J Virol 79 6459-6471 (2005)
  184. Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations. Singh D, Soni S, Khan S, Sarangi AN, Yennamalli RM, Aggarwal R, Veerapu NS. J Virol 94 e01327-19 (2020)
  185. HIV-1 envelope accessible surface and polarity: clade, blood, and brain. Sowmya G, Shamini G, Anita S, Sakharkar M, Mathura V, Rodriguez H, Levine AJ, Singer E, Commins D, Somboonwit C, Sinnott JT, Sidhu HS, Rajaseger G, Pushparaj PN, Kangueane P, Shapshak P. Bioinformation 6 48-56 (2011)
  186. Putative role of Tat-Env interaction in HIV infection. Poon S, Moscoso CG, Xing L, Kan E, Sun Y, Kolatkar PR, Vahlne AG, Srivastava IK, Barnett SW, Cheng RH. AIDS 27 2345-2354 (2013)
  187. Synthesis of Modular Building Blocks using Glycosyl Phosphate Donors for the Construction of Asymmetric N-Glycans. Dey S, Bajaj SO, Tsai TI, Lo HJ, Wu K, Wong CH. Tetrahedron 74 6003-6011 (2018)
  188. In-silico Structural Modeling of Human Immunodeficiency Virus Proteins. Elalouf A. Biomed Eng Comput Biol 14 11795972231154402 (2023)
  189. Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120. Vangala R, Sivan SK, Peddi SR, Manga V. J Comput Aided Mol Des 34 39-54 (2020)
  190. Molecular mechanism of HIV-1 gp120 mutations that reduce CD4 binding affinity. Kassler K, Sticht H. J Biomol Struct Dyn 32 52-64 (2014)
  191. Mutation in the D1 domain of CD4 receptor modulates the binding affinity to HIV-1 gp120. Shao J, Liu G, Lv G. RSC Adv 13 2070-2080 (2023)
  192. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer. Zhao C, Princiotto AM, Nguyen HT, Zou S, Zhao ML, Zhang S, Herschhorn A, Farrell M, Pahil K, Melillo B, Sambasivarao SV, Abrams C, Smith AB, Madani N, Sodroski J. J Virol 93 e01197-19 (2019)


Related citations provided by authors (1)

  1. Structure of an HIV gp120 Envelope Glycoprotein in Complex with the CD4 Receptor and a Neutralizing Human Antibody. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA Nature 393 648-659 (1998)

Quick links